Headache News and Research

Latest Headache News and Research

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine.

17 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

Designing infectious disease forecasting models to predict dengue epidemics

Dengue viruses are on the move. Spread among humans by mosquitoes, and across geographic boundaries through travel, the virus affects up to an estimated 390 million people every year around the world. In the U.S., recent outbreaks have occurred in Florida, Texas, Hawaii, and Puerto Rico. Scientists know one of the best ways to reduce the impact of the disease is to prepare healthcare providers by forecasting epidemics before they happen.

8 Jun 2015

GBD analysis shows over 95% of global population has health problems

Just one in 20 people worldwide (4·3%) had no health problems in 2013, with a third of the world's population (2·3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

8 Jun 2015

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.

3 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

For many people, bug bites and bee stings aren't a big deal beyond a small irritation. But for some, it could mean the start of a painful - possibly long-term or even deadly - experience.

1 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML).

1 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

1 Jun 2015

$Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma$

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).

1 Jun 2015

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Phase III results of Radiation Therapy Oncology Group 0537 indicate that acupuncture-like, transcutaneous electrical nerve stimulation (ALTENS) may be equally effective as pilocarpine, the current prescription medication in a pill, to treat radiation-induced xerostomia (dry mouth), according to a study published in the June 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

30 May 2015

Migraine surgery found effective among adolescent patients

As in adults, migraine surgery is effective for selected adolescent patients with severe migraine headaches that don't respond to standard treatments, reports a study in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2015

Headache News and Research

Latest Headache News and Research

CGRP monoclonal antibodies show promise in treating migraine

Novartis presents positive Phase III results of Farydak therapy at EHA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Designing infectious disease forecasting models to predict dengue epidemics

GBD analysis shows over 95% of global population has health problems

FDA grants exclusivity to Flublok influenza vaccine for 12 years

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Helsinn's Akynzeo for CINV prevention receives EC approval

Combination of Tafinlar and Mekinist drugs improves outcomes in patients with metastatic melanoma

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Pennsylvania physicians urge residents to take precautions against bug bites, bee stings

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Acupuncture-like TENS may be effective for treating radiation-induced xerostomia

Migraine surgery found effective among adolescent patients

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Headache News and Research

Latest Headache News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in